Soligenix CEO to Present at H.C. Wainwright Global Investment Conference
TL;DR
Soligenix CEO's presentation at H.C. Wainwright conference offers investors early insight into potential regulatory approvals and commercialization opportunities for rare disease treatments.
Soligenix will present at the H.C. Wainwright conference on September 5-10, 2025, with on-demand access and one-on-one meetings available through the platform.
Soligenix's rare disease treatments and vaccines address unmet medical needs, potentially improving lives worldwide through innovative biopharmaceutical solutions.
Soligenix develops novel photodynamic therapy for cutaneous T-cell lymphoma and heat-stabilized vaccines using proprietary ThermoVax technology for global health threats.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc., a late-stage biopharmaceutical company focused on rare disease treatments, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. The on-demand presentation will be available beginning September 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event.
The presentation is significant as it provides investors and the medical community with updates on Soligenix's pipeline of treatments addressing unmet medical needs in rare diseases. The company's Specialized BioTherapeutics business segment is advancing HyBryte™ (SGX301) toward potential commercialization as a novel photodynamic therapy for cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
Additional development programs include expansion of synthetic hypericin (SGX302) into psoriasis treatment, first-in-class innate defense regulator technology dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behcet's Disease. The company's Public Health Solutions business segment includes vaccine development programs that have received substantial government support.
This segment includes development of RiVax®, the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax™, the vaccine candidate for prevention of COVID-19. These programs incorporate the company's proprietary heat stabilization platform technology known as ThermoVax®. The development has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The conference presentation provides important visibility for Soligenix's dual-focused approach to both rare disease treatments and public health solutions, particularly as the company moves toward potential commercialization of its lead products. Investors and industry observers can access additional information through the company's newsroom at https://ibn.fm/SNGX.
Curated from InvestorBrandNetwork (IBN)
